As part of our coverage of this year’s DCAT Week, Pharmaceutical Technology® spoke with Hamilton Lenox, chief commercial officer at LGM Pharma about the expanding pharma market and the challenges such demand creates.
The pharmaceutical industry is expanding in a variety of areas, with an increased interest in domestic manufacturing in the United States, according to Hamilton Lenox, chief commercial officer at LGM Pharma. Pharmaceutical Technology® spoke with Lenox ahead of DCAT Week 2025, which is being held from March 17–20 in New York City, to discuss how market demand is impacting the industry and creating challenges for the supply chain.
“[One area] where we have continued to see focus and increased demand is more complex formulations in general … we're seeing increased needs in more niche service offerings," Lenox says. “Particularly, where we've seen a lot of growth recently [is] in our suppository demand, which is not traditionally the dosage form for North America for a lot of products. But in the past three years, we have seen increasing demand in the suppository space, some of that has been driven by women's health products, particularly post-COVID.”
Lenox points specifically to the challenge of drug shortages, which he says are increasing in length and add to market demand. “Historically, drug shortages, if you look at FDA data, have lasted anywhere from three to six months,” Lenox says. “In the COVID and post-COVID world, we're not only seeing an increasing amount of drug shortages, but those drug shortages are lasting longer, anywhere from six to 18 months, based on current FDA data as well. So, meeting that demand and ensuring reliable supply to avoid drug shortages [is a challenge].”
Click the above video to watch the interview.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.